Collagen Solutions PLC Director/PDMR Shareholding (8996B)

TIDMCOS

RNS Number : 8996B

Collagen Solutions PLC

25 September 2018

Collagen Solutions Plc

(the "Company" or the "Group")

Director/PDMR Dealing

The Company today announces that on 25 September 2018 David Evans, Chairman of the Company, has purchased 650,000 ordinary shares in the Company ("Ordinary Shares") at 3.75 pence per Ordinary Share.

Following these purchases, David Evans' total beneficial holding in the Company has increased to 43,187,411 Ordinary Shares representing 13.31 per cent. of the issued ordinary share capital of the Company.

The Company makes the following disclosures in accordance with article 19(3) of the Market Abuse Regulation:

 
  1     Details of the person discharging managerial responsibilities / person closely associated 
  a)    Name                                                           David Evans 
  2     Reason for the notification 
  a)    Position/status                                                Chairman 
  b)    Initial notification / Amendment                               Initial 
  3     Details of the issuer, emission allowance market participant, auction platform, auctioneer 
         or auction monitor 
  a)    Name                                                           COLLAGEN SOLUTIONS PLC 
  b)    LEI                                                            213800IFY1CVGRGETL95 
  4     Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) 
         each type of transaction; (iii) each date; and (iv) each place where transactions have been 
         conducted 
  a)    Description of the financial instrument, type of instrument    Ordinary shares of 1p each 
 
         Identification code                                            ISIN: GB00B94T6Y14 
  b)    Nature of the transaction                                      Purchase of Ordinary Shares 
  c)    Price(s) and volume(s)                                           Price(s)            Volume(s) 
                                                                          3.75p per share     650,000 
  d)    Aggregated information 
         - Aggregated volume                                            N/A - single transaction 
         - Price 
  e)    Date of the transaction                                        25 September 2018 
  f)    Place of the transaction                                       London Stock Exchange, XLON 
 

Enquiries:

 
 Collagen Solutions Plc 
 Jamal Rushdy, CEO                                                     Via Walbrook 
 Hilary Spence, CFO 
 
 Cenkos Securities Plc (Nominated 
  Adviser and Broker) 
 Steve Cox (Corporate Finance)                                   Tel: [phone] 
 Stephen Keys 
 
 Walbrook PR Ltd                      Tel: [phone] or [e-mail] 
 Anna Dunphy                                                     Mob: [phone] 
 Helen Cresswell                                                 Mob: [phone] 
 
 

About Collagen Solutions:

Collagen Solutions Plc is a global supplier, developer, and manufacturer of medical grade collagen, tissues, and related medical devices and components for use in regenerative medicine, medical devices and in-vitro diagnostics and research. The Company is also expanding its range of biomaterials-based finished medical devices based on its internal and acquired intellectual property for commercialisation with partners via licensing and distribution arrangements, including ChondroMimetic(R). The Company's products are used in a wide variety of applications including orthopaedics, cardiovascular, dental, plastic surgery, wound healing, neurology and urology.

For more information go to: www.collagensolutions.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHFKPDKQBKDNCB

(END) Dow Jones Newswires

September 25, 2018 10:05 ET (14:05 GMT)